Shan5 (DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine) / Sanofi - LARVOL DELTA

PHASE 1/2 STUDIES OF DZD8586 IN CLL/SLL PATIENTS AFTER COVALENT OR NON-COVALENT BTK INHIBITORS AND BTK DEGRADERS (EHA 2025) - P1, P2 | "The data from two clinical studies, TAI-SHAN5 (NCT05824585) and TAI-SHAN8 (NCT06539182, CTR20240120), were pooled for efficacy and safety analysis in patients with CLL/SLL. DZD8586 showed encouraging anti-tumor activity with well-tolerated and manageable safety profile in heavily pre-treated CLL/SLL patients, including patients with prior covalent BTKi, non-covalent BTKi, BTK degrader and Bcl-2 inhibitor treatment. The updated data will be presented at the meeting."

Clinical • IO biomarker • P1/2 data • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Disorders • Infectious Disease • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders. (ASCO 2025) - P1, P2 | " The data from two clinical studies, TAI-SHAN5 (NCT05824585) and TAI-SHAN8 (NCT06539182, CTR20240120), were pooled for the safety and efficacy analysis in patients with CLL/SLL... DZD8586 showed encouraging anti-tumor activity with a well tolerated and manageable safety profile in heavily pre-treated CLL/SLL patients, including patients with prior covalent BTKi, non-covalent BTKi, BTK degrader and Bcl-2 inhibitor treatment. PK/PD results confirmed dose/exposure-dependent pathway inhibition by DZD8586. The updated data will be presented at the meeting."

Clinical • IO biomarker • P1/2 data • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Disorders • Infectious Disease • Neutropenia • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma • LYN

"🗳️ begins, 🙏for support @IBUSurology @HillUrology @joeurol @lithohlr @stingrai78 @MazharSheikh14 @vishhanchanale @UroShergill @PeaPeaspot @drrickaz @drrachelhubbard @naeemsoomro @chrisharding123 @Sri_URO @EndoLuminalEndo @AnandUro @endouro @ahmadurology @Zeeshan52339599" (@shabi1009)

Study of Full Schedule (3-Dose of Shan6™) or Shan6™-Shan5®-Shan6™ Versus the Licensed Vaccine Shan5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants (clinicaltrialsregister.eu) - P3 | N=690 | Sponsor: Sanofi Pasteur

New P3 trial • Dermatology • Infectious Disease

"This made my day. @AnnieGunther5 @web3filmsonly @tortoricitheo @ericvautier @BlaecBejarano @TheFantasyHorn @wevatec @max60708275 @GlopesMd @pawankumaar667 @chrishan517 @phantazonia @scratchboom @man_shadowages" (@EindhovenNft)

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3 | N=460 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Pertussis • Pneumococcal Infections • Respiratory Diseases • Rotavirus Infections • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) vaccine administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in Thailand (clinicaltrialsregister.eu) - P3 | N=460 | Sponsor: Sanofi Pasteur

New P3 trial • Dermatology • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Pertussis • Respiratory Diseases • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Active, not recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Pediatrics • Pertussis • Respiratory Diseases • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Trial completion date: Mar 2022 ➔ Dec 2021; Trial primary completion date: Nov 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Pediatrics • Pertussis • Respiratory Diseases • Tetanus

"#GoodMorningTwitterWorld @ishita_002 @BuchHitakshi @bhogleharsha @AmbaniKishan5 @sejalbhagat54 @DrSapnaPatel @RupalAhir2 @kt_27070 @jappsh @hiralsalu @binal_71912 @_sally_17_06 @SeemaSh46712468 #MorningThoughts" (@RaiyaniJaimin)

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hepatitis B • Infectious Disease • Pediatrics • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Not yet recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company

Clinical • New P3 trial • Hepatitis B • Infectious Disease • Pediatrics • Tetanus

"@Shooshan5" (@antonyhsu)